AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 277 filers reported holding AMICUS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,155,021 | +19.1% | 1,821,959 | +23.0% | 0.01% | +33.3% |
| Q2 2023 | $18,604,952 | +119.8% | 1,481,286 | +67.1% | 0.01% | +200.0% |
| Q3 2021 | $8,466,000 | -30.1% | 886,513 | -29.4% | 0.00% | -50.0% |
| Q2 2021 | $12,113,000 | -2.7% | 1,256,561 | -0.3% | 0.00% | 0.0% |
| Q1 2021 | $12,450,000 | -54.3% | 1,260,156 | +6.8% | 0.00% | -55.6% |
| Q4 2020 | $27,239,000 | +1.4% | 1,179,684 | -38.0% | 0.01% | -10.0% |
| Q3 2020 | $26,850,000 | -7.5% | 1,901,591 | -1.2% | 0.01% | -9.1% |
| Q2 2020 | $29,024,000 | +76.5% | 1,924,647 | +8.2% | 0.01% | +37.5% |
| Q1 2020 | $16,440,000 | +7.9% | 1,779,191 | +13.7% | 0.01% | +33.3% |
| Q4 2019 | $15,240,000 | +36.3% | 1,564,725 | +12.2% | 0.01% | +50.0% |
| Q3 2019 | $11,185,000 | -20.8% | 1,394,663 | +23.3% | 0.00% | -33.3% |
| Q2 2019 | $14,114,000 | +1.9% | 1,130,944 | +11.1% | 0.01% | 0.0% |
| Q1 2019 | $13,846,000 | +44.9% | 1,018,099 | +2.1% | 0.01% | +20.0% |
| Q4 2018 | $9,557,000 | -19.1% | 997,582 | +2.2% | 0.01% | 0.0% |
| Q3 2018 | $11,807,000 | -2.6% | 976,570 | +25.8% | 0.01% | 0.0% |
| Q2 2018 | $12,125,000 | +5.3% | 776,230 | +1.4% | 0.01% | 0.0% |
| Q1 2018 | $11,512,000 | +16.8% | 765,421 | +11.7% | 0.01% | +25.0% |
| Q4 2017 | $9,859,000 | -3.3% | 685,115 | +1.3% | 0.00% | 0.0% |
| Q3 2017 | $10,196,000 | +2.9% | 676,117 | -31.3% | 0.00% | 0.0% |
| Q2 2017 | $9,907,000 | +41.2% | 983,776 | -0.0% | 0.00% | +33.3% |
| Q1 2017 | $7,016,000 | +43.2% | 983,981 | -0.2% | 0.00% | +50.0% |
| Q4 2016 | $4,898,000 | -5.9% | 985,504 | +40.1% | 0.00% | -33.3% |
| Q3 2016 | $5,205,000 | +37.8% | 703,372 | +1.7% | 0.00% | +50.0% |
| Q2 2016 | $3,776,000 | -37.5% | 691,659 | -3.3% | 0.00% | -33.3% |
| Q1 2016 | $6,042,000 | -11.8% | 714,977 | +1.3% | 0.00% | -25.0% |
| Q4 2015 | $6,848,000 | -31.1% | 706,045 | -0.7% | 0.00% | -33.3% |
| Q3 2015 | $9,946,000 | -99.9% | 710,953 | -29.7% | 0.01% | -14.3% |
| Q2 2015 | $14,313,276,000 | +14.7% | 1,011,539 | -11.8% | 0.01% | +16.7% |
| Q1 2015 | $12,473,985,000 | +34.5% | 1,146,506 | +2.9% | 0.01% | +20.0% |
| Q4 2014 | $9,271,201,000 | – | 1,114,327 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |